Episode Details

Julie Rubinstein, COO of Adaptive Biotechnologies, sold 179,703 shares, reducing her stake by 26%. The sale, part of a pre-set plan, netted her $2.4M. Despite the sale, Rubinstein remains aligned with shareholders through her remaining shares. Adaptive Biotechnologies, focusing on immune sequencing tech, saw a 72% stock rise over the past year.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/4b66f179fc56d148